RSV news - the latest biotech news from Labiotech.eu

Home RSV Page 2

Latest Posts

podcast 06

News and Trends 22 Jul 2022

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […]

July 22, 2022

RSV infections in children

News and Trends 21 Jul 2022

Vicebio exits stealth to work on next generation RSV vaccine

Vicebio Ltd, a biopharmaceutical company founded by Medicxi in 2019, has launched to accelerate the development of novel vaccines against life-threatening respiratory viral infections using its molecular clamp technology platform. The technology has been developed by Paul Young, Daniel Watterson, Keith Chappell and their groups at The University of Queensland (UQ), Brisbane, Australia. It was […]

July 21, 2022 - 4 minutesmins - By Jim Cornall

RSV infections in children

News and Trends 27 Jun 2022

OneThree Biotech completes build and optimization of AI model for RSV data

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, says its artificial intelligence (AI) partner, OneThree Biotech, Inc., has completed the build and optimization of a tailored AI model of Poolbeg’s respiratory syncytial virus (RSV) human challenge data and can now commence its analysis. Results are expected in Q4 2022. The tailored AI model is […]

June 27, 2022 - 4 minutesmins - By Jim Cornall

GSK lab

News and Trends 13 Jun 2022

GSK positive on RSV vaccine for older adults

GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. GSK said no unexpected safety concerns were observed. Dr Hal Barron, chief scientific officer and president, R&D, GSK, said, […]

June 13, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT